PMID- 26690343
OWN - NLM
STAT- MEDLINE
DCOM- 20160816
LR  - 20181113
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 213
IP  - 9
DP  - 2016 May 1
TI  - Tolerability of Early Measles-Mumps-Rubella Vaccination in Infants Aged 6-14 
      Months During a Measles Outbreak in The Netherlands in 2013-2014.
PG  - 1466-71
LID - 10.1093/infdis/jiv756 [doi]
AB  - BACKGROUND: In 2013-2014, a measles outbreak spread through the Netherlands. To 
      protect young infants, measles-mumps-rubella (MMR) vaccination was offered to 
      those aged 6-14 months in municipalities with routine first-dose MMR vaccine 
      coverage of <90%. We assessed the tolerability of this early administration of 
      MMR vaccine. METHODS: After study entry (n = 1866), parents of eligible infants 
      (n = 10 097) completed a questionnaire (n = 1304). For infants who received an 
      early MMR vaccine dose (n = 962), we asked for information about adverse events 
      (AEs) associated with the dose. AE frequencies were compared between infants aged 
      6-8, 9-11, and 12-14 months. Using multivariable logistic regression, we assessed 
      the association between the risk of AEs and age at early MMR vaccination. 
      RESULTS: The response rate was 13%. Parents of 59 infants (6.1%) and 350 infants 
      (36.4%) who received early MMR vaccination reported local and systemic AEs, 
      respectively. Parents of infants vaccinated at 6-8 months of age reported 
      systemic AEs less frequently (32%) than parents of children vaccinated at 9-11 
      months (45%) and 12-14 months (43%) of age (P= <.001). For local AEs, there were 
      no differences (5%, 7%, and 10%, respectively;P= .08). Compared with vaccination 
      at 6 months, all older infants except those aged 14 months showed an increased 
      risk for any AE and for systemic AEs starting 5-12 days after vaccination. 
      CONCLUSIONS: Early MMR vaccination is well tolerated, with the lowest AE 
      frequencies found in infants aged 6-8 months. It is a safe intervention for 
      protecting young infants against measles.
CI  - (c) The Author 2015. Published by Oxford University Press for the Infectious 
      Diseases Society of America.
FAU - van der Maas, Nicoline A T
AU  - van der Maas NA
AD  - Center for Infectious Disease Control, National Institute for Public Health and 
      the Environment, Bilthoven, The Netherlands.
FAU - Woudenberg, T
AU  - Woudenberg T
AD  - Center for Infectious Disease Control, National Institute for Public Health and 
      the Environment, Bilthoven, The Netherlands.
FAU - Hahne, S J M
AU  - Hahne SJ
AD  - Center for Infectious Disease Control, National Institute for Public Health and 
      the Environment, Bilthoven, The Netherlands.
FAU - de Melker, H E
AU  - de Melker HE
AD  - Center for Infectious Disease Control, National Institute for Public Health and 
      the Environment, Bilthoven, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20151221
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Measles-Mumps-Rubella Vaccine)
SB  - IM
MH  - Disease Outbreaks/*prevention & control
MH  - Female
MH  - Humans
MH  - Immunization Schedule
MH  - Infant
MH  - Male
MH  - Measles/*prevention & control
MH  - Measles-Mumps-Rubella Vaccine/*administration & dosage/*adverse 
      effects/therapeutic use
MH  - Netherlands/epidemiology
PMC - PMC4813742
OTO - NOTNLM
OT  - 6 months
OT  - early MMR
OT  - infants
OT  - measles
OT  - outbreak
OT  - tolerability
OT  - vaccination
EDAT- 2015/12/23 06:00
MHDA- 2016/08/17 06:00
PMCR- 2015/12/21
CRDT- 2015/12/23 06:00
PHST- 2015/09/28 00:00 [received]
PHST- 2015/12/14 00:00 [accepted]
PHST- 2015/12/23 06:00 [entrez]
PHST- 2015/12/23 06:00 [pubmed]
PHST- 2016/08/17 06:00 [medline]
PHST- 2015/12/21 00:00 [pmc-release]
AID - jiv756 [pii]
AID - 10.1093/infdis/jiv756 [doi]
PST - ppublish
SO  - J Infect Dis. 2016 May 1;213(9):1466-71. doi: 10.1093/infdis/jiv756. Epub 2015 
      Dec 21.